{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:13:16Z","timestamp":1786727596945,"version":"build-2736575974"},"reference-count":124,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,5,23]]},"DOI":"10.1080\/14656566.2020.1744564","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T06:48:55Z","timestamp":1585810135000},"page":"953-967","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["Current and new pharmacotherapy options for non-alcoholic steatohepatitis"],"prefix":"10.1080","volume":"21","author":[{"given":"Yoshio","family":"Sumida","sequence":"first","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Kasugai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Kasugai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Suita Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0533-z"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.003"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12645"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i31.7006"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140427"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16173011"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0167"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"cit0014","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al. REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u20132196.","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13425"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14209"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00907"},{"key":"cit0018","doi-asserted-by":"crossref","unstructured":"Patel K, Harrison SA, Elkashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial. Hepatology. 2020 [Epub ahead of print].","DOI":"10.1002\/hep.31205"},{"key":"cit0019","doi-asserted-by":"crossref","unstructured":"Chianelli D, Rucker PV, Roland J, et al. Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2020 [Epub ahead of print].","DOI":"10.1021\/acs.jmedchem.9b01621"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1193"},{"key":"cit0021","doi-asserted-by":"crossref","unstructured":"Lucas KJ, Lopez P, Lawitz E,\u00a0et al. Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim. Boston (USA): Liver meeting; 2019.","DOI":"10.1016\/j.dld.2019.12.129"},{"key":"cit0022","unstructured":"[cited 2019 Nov 20]. https:\/\/www.enanta.com\/investors\/news-releases\/press-release\/2019\/Enanta-Announces-Positive-Results-of-ARGON-1-Study-of-its-lead-FXR-Agonist-EDP-305-for-the-Treatment-of-NASH\/default.aspx"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1038\/srep42477"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.09.011"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32835cc949"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1072"},{"key":"cit0028","unstructured":"[cited 2019 Nov 20]. http:\/\/www.globenewswire.com\/news-release\/2019\/06\/11\/1866763\/0\/en\/CymaBay-Therapeutics-Reports-Topline-12-Week-Data-from-an-Ongoing-Phase-2b-Study-of-Seladelpar-in-Patients-with-Nonalcoholic-Steatohepatitis.html"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2015.02.007"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13634"},{"key":"cit0031","unstructured":"Gawrieh S, Noureddin M, Loo NM, et al. A phase 2, prospective, multicenter, double-blind, randomized study of saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcholic fatty liver disease and\/or nonalcoholic steatohepatitis (Evidences IV). Boston (USA): Linear meeting; 2019. #LO10."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26461"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01285"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208029"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210821"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1057"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1494153"},{"key":"cit0039","doi-asserted-by":"crossref","unstructured":"Harrison SA, Alkhouri N, Davison BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020;72(4):613\u2013626.","DOI":"10.1016\/j.jhep.2019.10.023"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf4823"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0200-y"},{"key":"cit0042","doi-asserted-by":"crossref","unstructured":"Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(8):537\u2013547.","DOI":"10.1016\/S2468-1253(18)30123-7"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-015-0070-9"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021115-105339"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.12.003"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00030"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30582-2"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22344"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1159\/000371670"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.9"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61177-7"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0208"},{"key":"cit0055","doi-asserted-by":"crossref","unstructured":"Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391(10126):1174\u20131185.","DOI":"10.1016\/S0140-6736(18)30474-4"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30425-2"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.032"},{"key":"cit0058","doi-asserted-by":"crossref","unstructured":"Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2019 [Epub ahead of print].","DOI":"10.1002\/hep.30590"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.056"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00573.2012"},{"key":"cit0061","doi-asserted-by":"crossref","unstructured":"Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u20132024.","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63967"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30328-8"},{"key":"cit0064","doi-asserted-by":"crossref","unstructured":"Lawitz EJ, Coste A, Poordad F, et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(12):1983\u20131991.e3.","DOI":"10.1016\/j.cgh.2018.04.042"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.07.009"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"cit0067","unstructured":"Lawitz E, Neff G, Ruane PJ, et al. Fenofibrate mitigates increase in serum triglycerides due to the acc inhibitor firsocostat in patients with advanced fibrosis due to nash: A phase 2 randomized trail. Boston (USA): Liver meeting; 2019."},{"key":"cit0068","unstructured":"Amin N, Carvajala-Gonzalez, Aggarwal N, et al. PF\u201005221304 (PF'1304), a Liver\u2010Targeted Acetyl\u2010Coa Carboxylase Inhibitor (ACCI), in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) Demonstrates Robust Reductions in Liver Fat and Alt \u2013 Phase 2a, Dose\u2010Ranging Study. Boston (USA): Liver meeting; 2019."},{"key":"cit0069","unstructured":"[cited 2019 Nov 20]. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01431521?term=MK-4074&rank=1"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-001-0824-3"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200306000-00012"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1107"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.038"},{"key":"cit0074","unstructured":"[cited 2019 Nov 20]. http:\/\/galmedpharma.investorroom.com\/download\/Aramchol_Late-Breaking_liver_meeting+AASLD_2018.pdf"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30674"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201402069"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30765"},{"key":"cit0078","author":"Esquejo RM","journal-title":"EBioMedicine"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.08.002"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194568"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12351"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12837"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13697"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15316"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12856"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30109-2"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13061"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13236"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"cit0095","unstructured":"Harrison S, Manghi FP, Smith WB, et al. LIK066 (Licogliflozin), an SGLT1\/2 inhibitor, robustly decreases alt and improves markers of hepatic and metobolic health in patients with non-alcholic fatty liver disease: interim analysis of a 12-week, randomized, placebo-controlled, phase 2a study. Boston (USA): Liver meeting; 2019."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28962"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13494"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32260-8"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73722"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04511.x"},{"key":"cit0102","first-page":"141","volume":"5","author":"Mizrahi M","year":"2012","journal-title":"J Inflamm Res"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.019"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.07.012"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30425-2"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12309"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.06.043"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477"},{"key":"cit0109","doi-asserted-by":"crossref","unstructured":"Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020 [Epub ahead of print].","DOI":"10.1002\/hep.31108"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105922"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.033"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29514"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13706"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2014.07.003"},{"key":"cit0115","doi-asserted-by":"crossref","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S, et al. GS-US-321-0105GS-US-321-0106 Investigators. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155(4):1140\u20131153.","DOI":"10.1053\/j.gastro.2018.07.006"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00794.x"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13816"},{"key":"cit0118","doi-asserted-by":"crossref","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334\u20131345.e5.","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105889"},{"issue":"3","key":"cit0120","first-page":"204","volume":"35","author":"Muto Y","year":"2006","journal-title":"Hepatol Res"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009061"},{"key":"cit0122","doi-asserted-by":"crossref","unstructured":"Jalali M, Mahmoodi M, Mosallanezhad Z, et al. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2020;48:102283.","DOI":"10.1016\/j.ctim.2019.102283"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30368"},{"key":"cit0124","author":"Sumida Y","journal-title":"Int J Mol Sci"}],"updated-by":[{"DOI":"10.1080\/14656566.2020.1794654","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000}}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1744564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T09:14:15Z","timestamp":1666257255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1744564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":124,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,5,23]]}},"alternative-id":["10.1080\/14656566.2020.1744564"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1744564","relation":{"correction":[{"id-type":"doi","id":"10.1080\/14656566.2020.1794654","asserted-by":"object"}]},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}